The Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the disease, may be able to be given as a set of two weekly shots at home, a study from drugmaker Eisai suggests ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, isn't a cure for the mind-damaging disease.. But the treatment promises to give patients such as Missie Meeks more time to live their daily ...

Kevin Smith, a resident of Clifton Park, is experiencing the benefits of a recently approved Alzheimer's drug, Leqembi, as he ...

Learn about side effects, uses, cost, and more for Leqembi (lecanemab-irmb), a prescription drug that treats Alzheimer’s disease in adults.

Patients who started Leqembi early continued to benefit from the drug over three years, showing a slower rate of cognitive decline compared to the other two groups, according to an Eisai presentation.

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on ...

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Leqembi has a boxed warning about the risk of ARIA. To learn more, see the introduction of this article. Your doctor will likely order a test to check for ApoE gene status before prescribing Leqembi.

Leqembi was far from a cure, and made no claim to be one. Over 18 months, it had slowed the advance of the disease by an average of 27 percent, or by about five months, in a clinical trial of some ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others.